Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
Consumer News and Business Channel
This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.
Read at original outlet ↗

